source
- Cerevance's solengepras cuts Parkinson off-time by 0.6 hours in Phase 3, advancing toward FDA reviewCerevance, a spinout from Takeda, reported that a high 150‑mg dose of its Parkinson's drug solengepras reduced daily "off time" by an average of 0.61 hours compared with placebo in the Phase 3 ARIS…
- Epkinly shows 51% lower risk of progression in frontline DLBCL trial, boosting hopes for expanded approvalNew Phase 3 data from the Epkinly and R-CHOP combination in diffuse large B cell lymphoma showed a 51% reduction in the risk of disease progression or death compared with standard therapy. The stud…BioSpace · 1mo agoPositive readoutPositive